Press Releases

1 June 2024
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
29 May 2024
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
22 May 2024
BioNTech to Evaluate NanoTag’s Target Labeling System in Different Therapeutic Areas
21 May 2024
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
17 May 2024
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
6 May 2024
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
22 April 2024
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
7 April 2024
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
20 March 2024
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
20 March 2024
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BioNTech disavows any obligation to update the information contained in such press releases after the date of their issuance.